Frederic Cumin

TL;DR: Aliskiren is the first in a novel class of renin inhibitors with the potential for treatment of hypertension and related cardiovascular diseases and employs a combination of molecular modelling and crystallographic structure analysis to design renin inhibitor lacking the extended peptide-like backbone of earlier inhibitors.

TL;DR: The design approach led to compounds with high in vitro affinity and specificity for renin, favourable bioavailability and excellent oral efficacy in lowering blood pressure in primates, which are potential therapeutic agents for the treatment of hypertension and related cardiovascular diseases.

TL;DR: The finding of renin mRNA and renin-like immunoreactivity in these tissues supports the notion that these tissues are sites for production of renIn, and suggests that posttranslational proteolysis or glycosylation of preprorenin varies in different tissues with consequent variations in immunore activity.

TL;DR: Analysis of the structure of feeding behavior revealed that prepro NPY and Y5 receptor antisense ODNs reduced food intake by inducing decreases in meal size and meal duration analogous to the orexigenic effects of NPY that are mediated by increases in these parameters.

TL;DR: The findings demonstrate that the short half life of leptin in the circulation is mainly determined by efficient renal clearance which is mediated in part by glomerular filtration.